The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation

NCT02013037 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Antibody-mediated Rejection
Hyperacute Rejection of Cardiac Transplant
Left Ventricular Dysfunction
Cardiac Allograft Vasculopathy
Heart Graft Dysfunction

Interventions

DRUG: Eculizumab

Sponsor

Cedars-Sinai Medical Center

Collaborators

[object Object]